MOA Mountain Lake Resources Inc.

Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the
"Corporation") announces positive results from experiments carried out with its
lead cancer drug candidate, COTI-2, in the cancer research laboratories of
Gordon Mills, M.D., Ph.D. Chair of the Department of Systems Biology and the
Co-director of the Khalifa Institute for Personalized Cancer Therapy at The
University of Texas MD Anderson Cancer Center in Houston, Texas. These
preclinical experiments were designed to definitively determine the effect of
COTI-2 in 32 common p53 mutations. The p53 gene is a tumor suppressing gene.
However, if the p53 gene is mutated, cancers often develop and grow out of
control.


"These results are encouraging given the central importance of p53 gene
mutations in many cancers," stated Dr. Mills. "Our research and data confirm
that COTI-2 is most active in mutant p53 tumors and the effect of COTI-2 in many
specific p53 mutations is striking. In addition, it appears that this effect can
be augmented by the presence of mutations in the AKT signaling pathway. The
preclinical data with COTI-2 in cell lines, animal models and the potential
mechanism of action warrant clinical trials. These clinical trials should
evaluate both response and the utility of biomarkers to select patients. If
COTI-2 proves to be highly active in people with p53 mutant tumors, this would
represent a breakthrough therapy for many cancer patients."


"New therapies that target mutations of genes such as p53 represent a promising
approach compared to conventional organ-specific cancer treatments," said Dr.
Wayne Danter, COTI's CEO. "These important results confirm and extend our
understanding of the mechanism of action ("MOA") of COTI-2. While previous
internal research indicated that COTI-2's effectiveness was related to the p53
mutation status of the tumor, the quality and amount of scientific data provided
by Dr. Mills are definitive and answer the remaining MOA questions posed by
potential licensing partners who are waiting for these results."


Extensive data from the experiments have demonstrated that:



1.  COTI-2 has a major mechanism of action that is dependent on p53 gene
    mutation status in human cancer cells. This is of significant
    therapeutic importance because at least 50% of all human cancers have at
    least one type of p53 mutation. 
2.  COTI-2 restores p53 protein to its normal function in human cancer cells
    with a wide range of common p53 gene mutations. This range includes
    three of the most common mutations found in about 20% of all human
    cancers. 
3.  COTI-2 is also effective in the presence of common mutations in the
    PI3K/AKT/mTOR cell signaling pathway. This means that COTI-2 is
    effective in cancers with mutations that lead to over expression of the
    tumor promoting protein AKT. 
4.  COTI-2 is generally less effective in human cancer cells with no mutant
    p53 protein; however, it is highly active in some cells where the p53
    gene is not mutated such as occurs in some cancers where the p53 gene
    has been lost. 
5.  The selection of patients for initial clinical trials could be based on
    the p53 gene mutation status of the patients' tumor. This would ensure
    that COTI-2 is administered to patients who are most likely to benefit
    the most. 
6.  A companion diagnostic test using the cell signaling proteins that
    respond to normal p53 protein could be developed to evaluate COTI-2
    therapy in tumors with specific p53 mutations. 



Other COTI-2 highlights:



--  Compound discovered using the Company's proprietary artificial
    intelligence-based drug discovery technology platform, CHEMSAS(R) 
--  Easily synthesized oral formulation with no stability issues 
--  Effective alone or in combination with approved cancer drugs 
--  Have four issued US patents with composition of matter protection to
    2030 



About p53 gene mutations:

Mutations of the p53 gene are the most common genetic alterations in human
cancers, occurring in:




--  More than 50% of all human cancers; 
--  Approximately 96% of ovarian cancers; 
--  Approximately 50% of non-small cell lung cancers; 
--  Between 40-50% of colorectal cancers; 
--  A wide range of other cancers, including breast, liver, bladder,
    pancreatic, esophagus and bone cancers. 



About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Mountain Lake Resources Inc. (TSXV:MOA)
Historical Stock Chart
From May 2024 to Jun 2024

Mountain Lake Resources Inc. (TSXV:MOA)
Historical Stock Chart
From Jun 2023 to Jun 2024